慢性乙型肝炎应用天晴复欣和甘利欣联合治疗的临床研究

Clinical research on treating chronic hepatitis B with Tianqing Fuxin and Ganlixin

目的:探讨慢性乙型肝炎予以天晴复欣及甘利欣联合治疗的临床研究。方法:入选我院2011年12月-2013年12月慢性乙型肝炎患者80例,按治疗方法的不同分入两组,每组40例,观察组予天晴复欣与甘利欣联合治疗,对照组予甘利欣治疗,比较两组的临床效果和治疗后HBV DNA及ALT水平。结果:观察组、对照组的临床有效率分别为90.0%、65.0%,结果具有统计学意义(P<0.05);治疗后观察组的HBV DNA水平显著优于对照组(P<0.05)。结论:慢性乙型肝炎病进行天晴复欣和甘利欣联合疗法,临床效果确切,可降低变异病毒的发生,可靠安全,值得临床推广。

Objective：To study the clinical efficacy of Tianqing Fuxin and Ganlixin on treating chronic hepatitis B. Methods：80 patients were randomly divided into two groups. The observation group was given Tianqing Fuxin and Ganlixin, another was given Ganlixin. Results：The total efficiency in the observation group was 90.0%, better than 65.0%in the control, the difference was statistically significant （P〈0.05）; the HBV and DNA levels in the observation were obviously better （P〈0.05）. Conclusion： Tianqing Fuxin and Ganlixin come with confirmed effects, it can reduce the occurrence of mutant virus, reliable and safe, and is worthy of clinical promotion.